Sensei biotherapeutics reports first quarter 2022 financial results and recent business highlights

- sns-101 preclinical data provide encouraging validation of ph-sensitive approach to inhibiting vista with high selectivity to treat solid tumors -

SNSE Ratings Summary

SNSE Quant Ranking